Drug Profile
Briciclib - Onconova Therapeutics
Alternative Names: Briciclib sodium; ON-013105; ON-014185Latest Information Update: 29 Jun 2021
Price :
$50
*
At a glance
- Originator Temple University
- Developer Onconova Therapeutics
- Class Antineoplastics; Phenols; Phenyl ethers; Small molecules; Sulfones
- Mechanism of Action Cyclin D1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 29 Jun 2021 Onconova Therapeutics terminates a phase I trial for Solid tumours (Metastatic disease) in USA (NCT02168725)
- 31 Dec 2020 Discontinued - Phase-I for Solid tumours (Metastatic disease) in USA (IV)
- 24 Apr 2020 Briciclib is still in phase I development in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA